GSK PLC ADR FSPONSORED ADR 1 ADR REPS 2 ORD SHS - COM (GSK)

Historical Holders from Q1 2014 to Q1 2025

Symbol
GSK on NYSE
CUSIP
37733W105
Type / Class
Equity / COM
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
887K
Holdings value
$30M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
6
Number of sells
-3
Average Value change %
0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of GSK PLC ADR FSPONSORED ADR 1 ADR REPS 2 ORD SHS - COM (GSK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 56 $2.17K $38.73 1
2024 Q4 887K $30M -$6.27M $33.82 6
2024 Q3 1.09M $44.4M -$7.4M $40.88 7
2024 Q2 1.27M $48.9M -$473K $38.50 7
2024 Q1 1.28M $54.9M +$448K $42.87 9
2023 Q4 1.27M $47.1M -$923K $37.06 8
2023 Q3 1.3M $47M +$725K $36.25 9
2023 Q2 1.28M $45.5M -$504K $35.64 8
2023 Q1 1.29M $45.9M +$865K $35.58 9
2022 Q4 1.27M $44.5M -$39.6M $35.14 12
2022 Q3 2.67M $78.7M -$13.5B $29.43 30
2022 Q2 319M $13.9B -$336M $43.53 808
2022 Q1 330M $14.4B +$163M $43.56 896
2021 Q4 309M $13.6B +$198M $44.10 889
2021 Q3 323M $12.4B +$152M $38.21 767
2021 Q2 319M $12.7B -$352M $39.82 781
2021 Q1 316M $11.3B +$543M $35.69 757
2020 Q4 282M $10.4B +$200M $36.80 796
2020 Q3 297M $11.2B -$400M $37.64 808
2020 Q2 305M $12.4B -$289M $40.79 820
2020 Q1 312M $11.8B +$916M $37.89 796
2019 Q4 288M $13.5B +$320M $46.99 877
2019 Q3 281M $12B +$122M $42.68 789
2019 Q2 279M $11.2B -$13M $40.02 785
2019 Q1 280M $11.7B +$201M $41.79 827
2018 Q4 274M $10.5B +$78.2M $38.21 784
2018 Q3 272M $10.9B +$211M $40.17 776
2018 Q2 247M $9.95B -$271M $40.31 773
2018 Q1 275M $10.8B +$122M $39.07 766
2017 Q4 273M $9.67B +$1.02B $35.47 749
2017 Q3 242M $9.84B +$527M $40.60 732
2017 Q2 229M $9.88B +$324M $43.12 768
2017 Q1 221M $9.32B +$255M $42.16 775
2016 Q4 208M $8.03B +$51.4M $38.51 752
2016 Q3 207M $8.92B -$126M $43.13 723
2016 Q2 210M $9.1B +$231M $43.34 728
2016 Q1 205M $8.33B -$334M $40.55 707
2015 Q4 215M $8.67B -$154M $40.35 705
2015 Q3 217M $8.37B -$453M $38.45 689
2015 Q2 230M $9.59B -$824M $41.65 706
2015 Q1 250M $11.5B -$101M $46.15 722
2014 Q4 254M $10.8B -$557M $42.74 711
2014 Q3 265M $12.2B -$647M $45.97 691
2014 Q2 278M $14.9B +$861M $53.48 710
2014 Q1 262M $14B -$161M $53.43 703